Biotech众生相:蓝鸟生物以最高1亿美元被收购

国际金融报
25 Feb

近日,明星基因疗法公司蓝鸟生物(bluebird bio)宣布被收购。即使这一结局早有预兆,但最高1亿美元的收购金额还是令市场唏嘘。毕竟蓝鸟生物曾是全球基因疗法领域的先驱,公司先后共推出三款“天价”产品,市值也一度逼近300亿美元。但安全性、定价过高、市场渠道难以打开、核心产品销售不及预期等问题也是蓝鸟生物不得不面对的现实。“卖身”或已是蓝鸟生物当下最好的结局。从百亿美元市值到1亿美元“卖身”...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10